Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer

Overview

A randomised double-blinded study, in which the patients either get methylprednisoloneacetate or saline solution in the mastectomy cavity to evaluate the efficacy of methylprednisoloneacetate in preventing seroma in patients operated for primary breast cancer.

Full Title of Study: “Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation?”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2011

Detailed Description

After mastectomy, up to 90 % of patients develops seroma in the cavity. The treatment is puncture, which is a small operation, but many patients have to come several times, and there is a risk of infection. In some cases further treatment can be postponed. Preventing seroma to develop would be an improvement in the treatment of breast cancer patients operated with mastectomy. An earlier study found that the seroma production was significant lower in the group who had Prednison injected directly into the cavity. In this study the patient are divided into two groups: patients who have mastectomy and axillary dissection and patients who have mastectomy and Sentinel Node operation. Each group are examined separately. Using Prednison in patients after operation could be a potential risk, but correct injection into the cavity will seldom give systemic side effects.

Interventions

  • Drug: methylprednisoloneacetate
    • Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.

Arms, Groups and Cohorts

  • breast cancer
    • Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity

Clinical Trial Outcome Measures

Primary Measures

  • number of punctures
    • Time Frame: 1 month after surgery

Participating in This Clinical Trial

Inclusion Criteria

  • women with primary breast cancer or Ductal carcinoma in situ, mastectomy plus either Sentinel Node or Axillary dissection, signed consent form Exclusion Criteria:

  • dissection of the axilla in les than 4 month, treatment with steroids, pregnancy, if the patient don't speak danish, allergy towards steroid, other medical conditions which the investigator find contradict participating

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Copenhagen University Hospital at Herlev
  • Collaborator
    • University Hospital, Gentofte, Copenhagen
  • Provider of Information About this Clinical Study
    • Charlotte Lanng, MD, Department of Breast Surgery ,Herlev Hospital
  • Overall Official(s)
    • Gro M Qvamme, MD, Principal Investigator,
  • Overall Contact(s)
    • Charlotte Lanng, MD, +4544884000, chalan01@heh.regionh.dk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.